Drugs / ALE.P03
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07169734 | Aug 2025 → Apr 2029 expected | cervical squamous cell carcinoma, colorectal cancer, intrahepatic cholangiocarcinoma, non-small cell squamous lung carcinoma +1 | Alentis Therapeutics AG | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALE.P03 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07169734 ↗ |
| Route | Intravenous | “ALE.P03, will be administered by IV infusion according to the assigned arms.” NCT07169734 ↗ |
| Target | CLDN1 | “A Phase I/II, Open-label, Multicenter Study of ALE.P03 (Claudin-1 Targeted Antibody-drug Conjugate) as a Monotherapy in Adult Patients With Selected Advanced or Metastatic...” NCT07169734 ↗ |